These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1532 related articles for article (PubMed ID: 23830904)

  • 1. Hybrid [¹⁸F]-FDG PET/MRI including non-Gaussian diffusion-weighted imaging (DWI): preliminary results in non-small cell lung cancer (NSCLC).
    Heusch P; Köhler J; Wittsack HJ; Heusner TA; Buchbender C; Poeppel TD; Nensa F; Wetter A; Gauler T; Hartung V; Lanzman RS
    Eur J Radiol; 2013 Nov; 82(11):2055-60. PubMed ID: 23830904
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Correlation of the apparent diffusion coefficient (ADC) with the standardized uptake value (SUV) in hybrid 18F-FDG PET/MRI in non-small cell lung cancer (NSCLC) lesions: initial results.
    Heusch P; Buchbender C; Köhler J; Nensa F; Beiderwellen K; Kühl H; Lanzman RS; Wittsack HJ; Gomez B; Gauler T; Schuler M; Forsting M; Bockisch A; Antoch G; Heusner TA
    Rofo; 2013 Nov; 185(11):1056-62. PubMed ID: 23860802
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diffusion weighted MRI and 18F-FDG PET/CT in non-small cell lung cancer (NSCLC): does the apparent diffusion coefficient (ADC) correlate with tracer uptake (SUV)?
    Regier M; Derlin T; Schwarz D; Laqmani A; Henes FO; Groth M; Buhk JH; Kooijman H; Adam G
    Eur J Radiol; 2012 Oct; 81(10):2913-8. PubMed ID: 22197090
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Correlation of simultaneously acquired diffusion-weighted imaging and 2-deoxy-[18F] fluoro-2-D-glucose positron emission tomography of pulmonary lesions in a dedicated whole-body magnetic resonance/positron emission tomography system.
    Schmidt H; Brendle C; Schraml C; Martirosian P; Bezrukov I; Hetzel J; Müller M; Sauter A; Claussen CD; Pfannenberg C; Schwenzer NF
    Invest Radiol; 2013 May; 48(5):247-55. PubMed ID: 23519008
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Correlation between standardized uptake value and apparent diffusion coefficient of neoplastic lesions evaluated with whole-body simultaneous hybrid PET/MRI.
    Rakheja R; Chandarana H; DeMello L; Jackson K; Geppert C; Faul D; Glielmi C; Friedman KP
    AJR Am J Roentgenol; 2013 Nov; 201(5):1115-9. PubMed ID: 24147485
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Does positron emission tomography data acquisition impact simultaneous diffusion-weighted imaging in a whole-body PET/MRI system?
    Buchbender C; Hartung-Knemeyer V; Heusch P; Heusner TA; Beiderwellen K; Wittsack HJ; Kühl H; Forsting M; Bockisch A; Antoch G; Lanzman RS
    Eur J Radiol; 2013 Feb; 82(2):380-4. PubMed ID: 23238361
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Whole-body diffusion-weighted imaging vs. FDG-PET for the detection of non-small-cell lung cancer. How do they measure up?
    Chen W; Jian W; Li HT; Li C; Zhang YK; Xie B; Zhou DQ; Dai YM; Lin Y; Lu M; Huang XQ; Xu CX; Chen L
    Magn Reson Imaging; 2010 Jun; 28(5):613-20. PubMed ID: 20418042
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diffusion-weighted MR imaging in comparison to integrated [¹⁸F]-FDG PET/CT for N-staging in patients with lung cancer.
    Pauls S; Schmidt SA; Juchems MS; Klass O; Luster M; Reske SN; Brambs HJ; Feuerlein S
    Eur J Radiol; 2012 Jan; 81(1):178-82. PubMed ID: 20932700
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Correlation between apparent diffusion coefficients on diffusion-weighted MRI and standardized uptake value on FDG-PET/CT in pancreatic adenocarcinoma.
    Sakane M; Tatsumi M; Kim T; Hori M; Onishi H; Nakamoto A; Eguchi H; Nagano H; Wakasa K; Hatazawa J; Tomiyama N
    Acta Radiol; 2015 Sep; 56(9):1034-41. PubMed ID: 25267921
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Measurement of apparent diffusion coefficient with simultaneous MR/positron emission tomography in patients with peritoneal carcinomatosis: comparison with 18F-FDG-PET.
    Schwenzer NF; Schmidt H; Gatidis S; Brendle C; Müller M; Königsrainer I; Claussen CD; Pfannenberg AC; Schraml C
    J Magn Reson Imaging; 2014 Nov; 40(5):1121-8. PubMed ID: 24923481
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Correlation of measurements from diffusion weighted MR imaging and FDG PET/CT in GIST patients: ADC versus SUV.
    Wong CS; Gong N; Chu YC; Anthony MP; Chan Q; Lee HF; Chu KM; Khong PL
    Eur J Radiol; 2012 Sep; 81(9):2122-6. PubMed ID: 21955604
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multifunctional profiling of non-small cell lung cancer using 18F-FDG PET/CT and volume perfusion CT.
    Sauter AW; Winterstein S; Spira D; Hetzel J; Schulze M; Mueller M; Pfannenberg C; Claussen CD; Klotz E; Hann von Weyhern C; Horger MS
    J Nucl Med; 2012 Apr; 53(4):521-9. PubMed ID: 22414637
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Correlation of the apparent diffusion coefficient (ADC) with the standardized uptake value (SUV) in lymph node metastases of non-small cell lung cancer (NSCLC) patients using hybrid 18F-FDG PET/MRI.
    Schaarschmidt BM; Buchbender C; Nensa F; Grueneisen J; Gomez B; Köhler J; Reis H; Ruhlmann V; Umutlu L; Heusch P
    PLoS One; 2015; 10(1):e0116277. PubMed ID: 25574968
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Whole-body diffusion-weighted MRI and (18)F-FDG PET/CT can discriminate between different lymphoma subtypes.
    Mosavi F; Wassberg C; Selling J; Molin D; Ahlström H
    Clin Radiol; 2015 Nov; 70(11):1229-36. PubMed ID: 26208992
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diffusion-weighted MRI in early chemotherapy response evaluation of patients with diffuse large B-cell lymphoma--a pilot study: comparison with 2-deoxy-2-fluoro- D-glucose-positron emission tomography/computed tomography.
    Wu X; Kellokumpu-Lehtinen PL; Pertovaara H; Korkola P; Soimakallio S; Eskola H; Dastidar P
    NMR Biomed; 2011 Dec; 24(10):1181-90. PubMed ID: 21387451
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Standardized uptake values for [¹⁸F] FDG in normal organ tissues: comparison of whole-body PET/CT and PET/MRI.
    Heusch P; Buchbender C; Beiderwellen K; Nensa F; Hartung-Knemeyer V; Lauenstein TC; Bockisch A; Forsting M; Antoch G; Heusner TA
    Eur J Radiol; 2013 May; 82(5):870-6. PubMed ID: 23394765
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prediction of clinical outcome after stereotactic body radiotherapy for non-small cell lung cancer using diffusion-weighted MRI and (18)F-FDG PET.
    Iizuka Y; Matsuo Y; Umeoka S; Nakamoto Y; Ueki N; Mizowaki T; Togashi K; Hiraoka M
    Eur J Radiol; 2014 Nov; 83(11):2087-92. PubMed ID: 25174774
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Thoracic staging in lung cancer: prospective comparison of 18F-FDG PET/MR imaging and 18F-FDG PET/CT.
    Heusch P; Buchbender C; Köhler J; Nensa F; Gauler T; Gomez B; Reis H; Stamatis G; Kühl H; Hartung V; Heusner TA
    J Nucl Med; 2014 Mar; 55(3):373-8. PubMed ID: 24504054
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preoperative mediastinal and hilar nodal staging with diffusion-weighted magnetic resonance imaging and fluorodeoxyglucose positron emission tomography/computed tomography in patients with non-small-cell lung cancer: which is better?
    Wu LM; Xu JR; Gu HY; Hua J; Chen J; Zhang W; Haacke EM; Hu J
    J Surg Res; 2012 Nov; 178(1):304-14. PubMed ID: 22541065
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Newly diagnosed lymphoma: initial results with whole-body T1-weighted, STIR, and diffusion-weighted MRI compared with 18F-FDG PET/CT.
    van Ufford HM; Kwee TC; Beek FJ; van Leeuwen MS; Takahara T; Fijnheer R; Nievelstein RA; de Klerk JM
    AJR Am J Roentgenol; 2011 Mar; 196(3):662-9. PubMed ID: 21343511
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 77.